OverviewSuggest Edit

Moleculin Biotech is a pharmaceutical company focused on the development of anti-cancer drug candidates. Its lead product candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company is also engaged in the preclinical development of additional drug candidates, including additional immune and transcription modulators as well as metabolism and glycosylation inhibitors.
TypePublic
Founded2006
HQHouston, TX, US
Websitemoleculin.com

Latest Updates

Employees (est.) (Dec 2019)11(+23%)
Revenue (FY, 2020)$0
Share Price (Jun 2021)$4(+6%)
Cybersecurity ratingBMore

Key People/Management at Moleculin Biotech

Walter V. Klemp

Walter V. Klemp

Founder, President, CEO and Chairman
Donald Picker

Donald Picker

Chief Science Officer
Robert Shepard

Robert Shepard

Chief Medical Officer – Annamycin
Sandra Silberman

Sandra Silberman

Chief Medical Officer – New Products
Jonathan P. Foster

Jonathan P. Foster

Executive VP & Chief Financial Officer
Show more

Moleculin Biotech Office Locations

Moleculin Biotech has an office in Houston
Houston, TX, US (HQ)
5300 Memorial Dr #950
Show all (1)

Moleculin Biotech Financials and Metrics

Moleculin Biotech Revenue

USD

Net income (FY, 2020)

(17.3m)

EBIT (FY, 2020)

(19.7m)

Market capitalization (7-Jun-2021)

112.4m

Closing stock price (7-Jun-2021)

4.0

Cash (31-Dec-2020)

15.2m

EV

97.3m
Moleculin Biotech's current market capitalization is $112.4 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

4.1m5.2m6.3m6.8m

R&D expense

4.5m9.7m11.0m12.8m

Operating expense total

8.6m15.0m17.5m19.5m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

General and administrative expense

1.4m1.2m1.2m1.6m1.5m1.7m1.8m1.7m1.7m

R&D expense

1.2m4.2m1.3m2.9m2.1m2.8m3.2m3.3m4.4m

Operating expense total

2.6m5.5m2.6m4.6m3.6m4.5m5.1m5.0m6.2m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

7.7m7.1m10.7m15.2m

Prepaid Expenses

588.0k840.0k2.7m2.0m

Current Assets

8.3m8.0m13.5m17.2m

PP&E

33.0k463.0k316.0k483.0k
Quarterly
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(9.8m)(11.9m)(13.2m)

Depreciation and Amortization

18.0k68.0k199.0k200.0k

Accounts Payable

411.0k436.0k907.0k(1.0m)

Cash From Operating Activities

(7.3m)(12.2m)(17.2m)(17.8m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(1.9m)(7.1m)(9.1m)(4.0m)(5.3m)(9.4m)(1.2m)(11.3m)(14.7m)

Depreciation and Amortization

8.0k15.0k27.0k48.0k97.0k147.0k46.0k98.0k154.0k

Accounts Payable

(239.0k)866.0k(25.0k)1.6m11.0k1.9m(947.0k)(235.0k)(810.0k)

Cash From Operating Activities

(2.8m)(6.3m)(9.1m)(3.8m)(9.2m)(12.5m)(4.3m)(9.3m)(14.6m)
USDFY, 2017

Financial Leverage

1.1 x
Show all financial metrics

Moleculin Biotech Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Moleculin Biotech Online and Social Media Presence

Embed Graph

Moleculin Biotech News and Updates

Thinking about buying stock in Galectin Therapeutics, Moleculin Biotech, Microvision, Nikola Corp, or Ardelyx?

NEW YORK, April 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GALT, MBRX, MVIS, NKLA, and ARDX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding...

Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020

HOUSTON, March 24, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the year...

Moleculin Announces Full Exercise of Over-Allotment Option

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the underwriters of its public offering announced February 3, 2021 have exerci…

Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the Agencja Badań Medycznych (The Medical Research Agency) a Polish state agency r…

Moleculin Announces Pricing Of $67.8 Million Underwritten Public Offering

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the pricing of an underwritten public offering of an aggregate of 14,273,684 shares…

Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended September 30, 2020

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the quarter ended September 30, 2020 and provided a business …
Show more

Moleculin Biotech Blogs

Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

- Annamycin granted Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases - Interim data expected in the second half of 2022 HOUSTON, June 21, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a c…

Moleculin Announces Inclusion in the Russell 2000® Index

HOUSTON, June 15, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that as part of the annual reconstitution …

Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

- Annamycin was designed to potentially become the first ever non-cardiotoxic anthracycline and has been shown in animal models to accumulate in the lungs at more than 30 times the level of doxorubicin (current standard of care) - Patient enrollment on track to begin this quarter - Interim data expe…

Moleculin Biotech to Present at the Q2 Virtual Investor Summit

Live video webcast with President and CEO, Walter Klemp, on Monday, May 17, 2021 at 12:30 PM ET HOUSTON, May 11, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targe…

Moleculin Announces Full Exercise of Over-Allotment Option

Increases Gross Proceeds to Approximately $78 Million HOUSTON, Feb. 10, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, tod…

Moleculin Announces Pricing Of $67.8 Million Underwritten Public Offering

HOUSTON, Feb. 3, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the pricing of an underwritten public offer…
Show more

Moleculin Biotech Frequently Asked Questions

  • When was Moleculin Biotech founded?

    Moleculin Biotech was founded in 2006.

  • Who are Moleculin Biotech key executives?

    Moleculin Biotech's key executives are Walter V. Klemp, Donald Picker and Robert Shepard.

  • How many employees does Moleculin Biotech have?

    Moleculin Biotech has 11 employees.

  • Who are Moleculin Biotech competitors?

    Competitors of Moleculin Biotech include Northwest Biotherapeutics, Onconova Therapeutics and AVEO Pharmaceuticals.

  • Where is Moleculin Biotech headquarters?

    Moleculin Biotech headquarters is located at 5300 Memorial Dr #950, Houston.

  • Where are Moleculin Biotech offices?

    Moleculin Biotech has an office in Houston.

  • How many offices does Moleculin Biotech have?

    Moleculin Biotech has 1 office.